- Home
- NMI vs ARMP Comparison
NMI vs ARMP Comparison
Compare NMI & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMI | ARMP |
|---|---|---|
| Founded | 1988 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.9M | 125.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NMI | ARMP |
|---|---|---|
| Price | $10.18 | $8.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 28.4K | ★ 43.1K |
| Earning Date | 01-01-0001 | 03-19-2026 |
| Dividend Yield | ★ 4.10% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,054,000.00 |
| Revenue This Year | N/A | $4.48 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.30 | $0.90 |
| 52 Week High | $10.05 | $16.34 |
Technical Indicators
Market Signals| Indicator | NMI | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 57.55 | 61.88 |
| Support Level | $10.06 | $7.44 |
| Resistance Level | $10.25 | $8.36 |
| Average True Range (ATR) | 0.11 | 0.58 |
| MACD | 0.02 | 0.09 |
| Stochastic Oscillator | 79.07 | 85.93 |
Price Performance
Historical ComparisonAbout NMI Nuveen Municipal Income Fund Inc.
Nuveen Municipal Income Fund Inc is a diversified, closed-end management investment company. The Fund's investment objective is to provide a high level of current income exempt from federal income tax, which it seeks to achieve by investing mainly in a diversified portfolio of tax-exempt municipal obligations.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.